Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	LABEL_sum_dosing_errors int64	LABEL_dosing_error_rate float32	LABEL_wilson_label int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_count_Accidental overdose int64	METADATA_count_Drug administration error int64	METADATA_count_Incorrect drug administration duration int64	METADATA_count_Intentional overdose int64	METADATA_count_Multiple drug overdose int64	METADATA_count_Overdose int64	METADATA_count_Treatment noncompliance int64	METADATA_wilson_lower_bound float32
[ 5 ]	87	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of this study is to evaluate the immediate synergistic effect on the relief of severe acid-related dyspeptic pain by adding intravenous pantoprazole to the combination of oral antacid and antispasmodic agent (the conventional treatment).	Acid-related dyspepsia is common among the population. Number of these patients may have so severe symptoms that can lead them to the emergency department. Mixtures of antacid and antispasmodic were widely used over decades to relieve this acute pain with moderate, yet questionable, improvement in pain score. Proton pu...	Dyspepsia Emergency Pain	Dyspepsia Emergency treatment Pantoprazole Antacid Pain measurement	null	2	arm 1: Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline arm 2: Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole	[ 1, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 10 ml of 0.9% sodium chloride solution intervention 2: 80 mg of intravenous pantoprazole intervention 3: 30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide) intervention 4: 20 mg of intravenous hyoscine butylbromide	intervention 1: Normal saline intervention 2: Pantoprazole intervention 3: Oral antacid intervention 4: Hyoscine butylbromide	1	Patumwan \| Bangkok \| Thailand \| N/A \| N/A	87	0	0	0	NCT01281501	1COMPLETED	2011-10-01	2011-01-01	Chulalongkorn University	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 0 ]	20	NA	SINGLE_GROUP	null	0NONE	false	0ALL	false	This study will further investigate the Masimo SpHb \[FDA Approved\] continuous non-invasive hemoglobin monitor in spine surgery patients. (See NCT00792597) We will investigate the effect of enhanced circulation to the finger (which will be attached to the sensor) following a local injection (digital block) of lidocain...	We have completed a study with 20 patients using the latest version of the SpHb monitor software and finger sensor. The purpose of this study is to assess the accuracy of the SpHb reading as it relates to a standard laboratory hemoglobin value (tHb) following the digital block.	Digital Block		null	1	arm 1: None	[ 0 ]	2	[ 0, 1 ]	intervention 1: One dose of lidocaine 2% injected locally into one finger (2 mls total) intervention 2: Masimo SpHb continuous hemoglobin monitor	intervention 1: Lidocaine digital block intervention 2: Masimo SpHb continuous hemoglobin monitor	1	San Francisco \| California \| United States \| -122.41942 \| 37.77493	20	0	0	0	NCT01284296	1COMPLETED	2011-10-01	2010-08-01	University of California, San Francisco	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	125	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.	null	Glaucoma, Open-Angle Ocular Hypertension		null	6	arm 1: AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1. arm 2: AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2. arm 3: AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of...	[ 0, 0, 0, 1, 0, 5 ]	3	[ 0, 0, 0 ]	intervention 1: AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2. intervention 2: bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2. intervention 3: bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both e...	intervention 1: AGN-210669 intervention 2: bimatoprost intervention 3: bimatoprost vehicle	1	Austin \| Texas \| United States \| -97.74306 \| 30.26715	249	0	0	0	NCT01291108	1COMPLETED	2011-10-01	2011-04-01	Allergan	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	-0
[ 3 ]	745	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of this study is to evaluate the analgesic efficacy of Dexketoprofen Trometamol and Tramadol Hydrochloride given in combinations and the analgesic efficacy of each single component in comparison to placebo on moderate to severe pain following impacted third mandibular molar tooth extraction. Ibuprofen will ...	The aim of this study is to develop a combination of Dexketoprofen Trometamol (DKP.TRIS) and Tramadol Hydrochloride (TRAM.HCl) for the treatment of acute moderate to severe pain, based on the rationale that more than one drug is necessary in most patients suffering of acute and chronic pain, particularly of moderate to...	Pain	Moderate to severe pain Postoperative pain Analgesics Dexketoprofen Tramadol	null	10	arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None arm 7: None arm 8: None arm 9: None arm 10: None	[ 2, 1, 1, 1, 1, 1, 0, 0, 0, 0 ]	10	[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: Dexketoprofen Trometamol low dose, oral film-coated table, once intervention 2: Dexketoprofen Trometamol high dose, oral film-coated table, once intervention 3: Tramadol Hydrochloride low dose, oral film-coated table, once intervention 4: Tramadol Hydrochloride high dose, oral film-coated table, once in...	intervention 1: Dexketoprofen Trometamol intervention 2: Dexketoprofen Trometamol intervention 3: Tramadol Hydrochloride intervention 4: Tramadol Hydrochloride intervention 5: Ibuprofen intervention 6: Placebo intervention 7: Dexketoprofen Trometamol + Tramadol Hydrochloride intervention 8: Dexketoprofen Trometamol + T...	16	Greifswald \| Mecklenburg-Vorpommern \| Germany \| 13.40244 \| 54.08905 Kiel \| Schleswig-Holstein \| Germany \| 10.13489 \| 54.32133 Budapest \| Budapest \| Hungary \| 19.04045 \| 47.49835 Pisa \| Pisa \| Italy \| 10.4036 \| 43.70853 Verona \| Verona \| Italy \| 10.9938 \| 45.43854 Warsaw \| Masovian Voivodeship \| Poland \| 21.01178 \| 52.2...	611	0	0	0	NCT01307020	1COMPLETED	2011-10-01	2011-02-01	Menarini Group	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	97	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	1FEMALE	false	This study is designed to provide information about the bone anabolic properties and absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of 24 weeks to postmenopausal women with osteoporosis.	The choice of a 24-week treatment period was based on published studies of PTH which demonstrate its potential to produce a statistically significant increase in BMD in patients with postmenopausal osteoporosis within that observation period.	Postmenopausal Osteoporosis	Osteoporosis Bone Diseases, Metabolic Bone Diseases Bone Density Conservation Agents	null	3	arm 1: PTH(1-31) 5 mg tablet, once daily arm 2: Placebo matching tablet, once daily arm 3: Forsteo (teriparatide) 20 mcg SC Injection, once daily	[ 0, 2, 1 ]	3	[ 0, 0, 0 ]	intervention 1: A recombinant 1-31 amino acid fragment of PTH. intervention 2: None intervention 3: A recombinant 1-34 amino acid fragment of PTH.	intervention 1: PTH analog intervention 2: Placebo intervention 3: Forsteo (Teriparatide)	4	Aalborg \| N/A \| Denmark \| 9.9187 \| 57.048 Ballerup Municipality \| N/A \| Denmark \| 12.36328 \| 55.73165 Vejle \| N/A \| Denmark \| 9.5357 \| 55.70927 Tallinn \| N/A \| Estonia \| 24.75353 \| 59.43696	97	0	0	0	NCT01321723	1COMPLETED	2011-10-01	2011-02-01	Unigene Laboratories Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	121	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	1FEMALE	false	The purpose of this study is to determine whether preoperatively administered hydrocodone/acetaminophen (HC/APAP) reduces pain during a first trimester surgical abortion.	The investigators plan to conduct a double-blinded randomized placebo-controlled trial of 120 women undergoing elective first trimester surgical abortion. These women will be premedicated with either two tabs of 5/350 hydrocodone/acetaminophen or 2 tabs of a placebo. All subjects will receive ibuprofen and lorazepam pr...	Pain	Pain during first trimester surgical abortion	null	2	arm 1: Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure. Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure. arm 2: Subject will receive placebo 45-90 minutes prior to abortion procedure. Subject will also recieve ibuprofen, ...	[ 1, 2 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure. intervention 2: Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure. intervention 3: 800 mg oral ibuprofen intervention 4: 2 mg oral lorazepam intervention 5: 20 ml 1% buffe...	intervention 1: Hydrocodone/acetaminophen intervention 2: Placebo intervention 3: Ibuprofen intervention 4: Lorazepam intervention 5: Lidocaine	2	Portland \| Oregon \| United States \| -122.67621 \| 45.52345 Portland \| Oregon \| United States \| -122.67621 \| 45.52345	121	0	0	0	NCT01330459	1COMPLETED	2011-10-01	2011-02-01	Elizabeth Micks	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3, 4 ]	101	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.	null	Allergic Conjunctivitis		null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 1 drop in each eye at 3 separate times during a 21 day period intervention 2: 1 drop in each eye at 3 separate times during a 21 day period intervention 3: 1 drop in each eye at 3 separate times during a 21 day period intervention 4: 1 drop in each eye at 3 separate times during a 21 day period	intervention 1: AC-170 0.05% intervention 2: AC-170 0.1% intervention 3: AC-170 0.24% intervention 4: AC-170 0%	1	Andover \| Massachusetts \| United States \| -71.137 \| 42.65843	101	0	0	0	NCT01332188	1COMPLETED	2011-10-01	2011-04-01	Aciex Therapeutics, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	103	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	false	The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.	The primary objective of this study is to demonstrate efficacy relative to placebo of PT001 MDI in patients with moderate to severe chronic obstructive pulmonary disease (COPD) within the range of doses evaluated in this protocol. To this end, each dose of PT001 MDI will be compared to placebo with respect to the prima...	Chronic Obstructive Pulmonary Disease	COPD	null	6	arm 1: PT001 MDI arm 2: PT001 MDI arm 3: PT001 MDI arm 4: PT001 MDI arm 5: Ipratropium Bromide HFA Inhalation Aerosol arm 6: PT001 Placebo MDI	[ 0, 0, 0, 0, 1, 2 ]	3	[ 0, 0, 10 ]	intervention 1: PT001 MDI administered as two puffs BID for 7 days intervention 2: Taken as 2 inhalations of the 17 µg per actuation strength MDI QID intervention 3: Matching placebo to PT001 MDI administered as two puffs BID for 7 days	intervention 1: PT001 MDI intervention 2: Ipratropium Bromide HFA Inhalation Aerosol intervention 3: Placebo MDI	8	Panama City \| Florida \| United States \| -85.65983 \| 30.15946 Winter Park \| Florida \| United States \| -81.33924 \| 28.6 Cherry Hill \| New Jersey \| United States \| -75.03073 \| 39.93484 Summit \| New Jersey \| United States \| -74.36468 \| 40.71562 Charlotte \| North Carolina \| United States \| -80.84313 \| 35.22709 Medford \| Ore...	288	0	0	0	NCT01350128	1COMPLETED	2011-10-01	2011-05-01	Pearl Therapeutics, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 2 ]	35	RANDOMIZED	CROSSOVER	7BASIC_SCIENCE	0NONE	true	0ALL	false	The purposes of this study are to compare how much of LY2409021 enters the bloodstream and how long the body takes to get rid of the drug when different formulations of LY2409021 are given, and when LY2409021 is taken with or without food. The study will be conducted in 2 cohorts. Each cohort will have 3 study periods...	null	Healthy Volunteers	Healthy Volunteers Bioavailability	null	6	arm 1: A 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state arm 2: Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal arm 3: Single 20 mg LY2409021 test form with medium particle size administer...	[ 0, 0, 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered orally intervention 4: Administered orally	intervention 1: LY2409021 Reference Form intervention 2: LY2409021 Test-Med Formulation (medium particle size) intervention 3: LY2409021 Test-High Formulation (high particle size) intervention 4: LY2409021 Test-Low Formulation (low particle size)	1	Singapore \| N/A \| Singapore \| 103.85007 \| 1.28967	98	0	0	0	NCT01354496	1COMPLETED	2011-10-01	2011-04-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	168	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The primary purpose of this study was to evaluate the analgesic effect and safety of hydrocodone/acetaminophen extended release compared to placebo.	This phase 2, multicenter, double-blind (DB), placebo-controlled, randomized withdrawal study compared the analgesic efficacy and safety of hydrocodone/acetaminophen extended release to placebo in subjects with moderate to moderately severe chronic lower back pain (CLBP). Participants met pre-defined criteria at the co...	Chronic Low Back Pain		null	3	arm 1: Hydrocodone/acetaminophen extended release, 2 tablets twice daily arm 2: Hydrocodone/acetaminophen extended release, 1 tablet twice daily arm 3: Placebo, 1 tablet twice daily	[ 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: hydrocodone/acetaminophen extended release intervention 2: Placebo	17	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Burbank \| California \| United States \| -118.30897 \| 34.18084 Lomita \| California \| United States \| -118.31507 \| 33.79224 DeLand \| Florida \| United States \| -81.30312 \| 29.02832 Oldsmar \| Florida \| United...	314	0	0	0	NCT01364922	1COMPLETED	2011-10-01	2011-06-01	AbbVie (prior sponsor, Abbott)	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	-0
[ 4 ]	340	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This study will investigate the efficacy of esomeprazole 20 mg once a day in the treatment of frequent heartburn	null	Heartburn	Heartburn	null	2	arm 1: None arm 2: None	[ 0, 2 ]	1	[ 0 ]	intervention 1: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose	intervention 1: Esomeprazole	10	Sacramento \| California \| United States \| -121.4944 \| 38.58157 Seminole \| Florida \| United States \| -82.79121 \| 27.83975 Meridian \| Idaho \| United States \| -116.39151 \| 43.61211 Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Metairie \| Louisiana \| United States \| -90.15285 \| 29.98409 Omaha \| Nebraska \| U...	331	0	0	0	NCT01370525	1COMPLETED	2011-10-01	2011-08-01	AstraZeneca	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	341	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This study will investigate the efficacy of esomeprazole 20 mg once a day in the treatment of frequent heartburn	null	Heartburn	Heartburn	null	2	arm 1: None arm 2: None	[ 0, 2 ]	1	[ 0 ]	intervention 1: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose	intervention 1: Esomeprazole	10	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Westlake Village \| California \| United States \| -118.80565 \| 34.14584 Lexington \| Kentucky \| United States \| -84.47772 \| 37.98869 Rochester \| New York \| United States \| -77.61556 \| 43.15478 Dakota ...	320	0	0	0	NCT01370538	1COMPLETED	2011-10-01	2011-08-01	AstraZeneca	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 0 ]	20	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Isoproterenol is used as a cardiac stimulant in electrophysiology studies (EP). Preliminary data suggests that administration of isoproterenol increases the Bispectral index (BIS). BIS is used to monitor neuronal signals under anesthesia. The BIS level is suggested to correspond to the level of consciousness. We hypoth...	Isoproterenol is a direct acting Beta-1 and Beta-2 agonist useful for its effects on bronchodilation and myocardial contractility. Its CNS side effects include nervousness, headache, dizziness, restlessness, insomnia, anxiety, tension, blurring of vision, fear, and excitement. In addition to our preliminary data, two c...	Intraoperative Awareness	Isoproterenol Bispectral index (BIS) electrophysiology studies (EPS)	null	1	arm 1: 30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent pati...	[ 0 ]	1	[ 0 ]	intervention 1: patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).	intervention 1: Isoproterenol	1	New York \| New York \| United States \| -74.00597 \| 40.71427	20	0	0	0	NCT01377636	1COMPLETED	2011-10-01	2009-08-01	NYU Langone Health	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	11	RANDOMIZED	SINGLE_GROUP	4SUPPORTIVE_CARE	2DOUBLE	true	0ALL	false	In this study the investigators will be comparing two different types of anesthetic, a numbing eye drop and a numbing gel, to test if they are equally effective or if one has a better outcome in terms of the level of comfort you experience one hour and one day after your surgery. The two medications are commonly used a...	Outcome measures involve comparing the right eye and left eye for severity of 12 different symptoms, that are recorded in severity on a 1-5 scale. A score of 1 means no symptoms and 5 means severe. The 12 measurements include sharp pain, dull ache, pain during movement, stinging sensation, itching, light sensitivity, w...	Pain	efficacy comfort	null	2	arm 1: Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK. arm 2: Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: 0.5% Tetracaine Right eye / 2% Lidocaine Left eye intervention 2: 0.5% Tetracaine Left eye / 2% Lidocaine Right eye	intervention 1: Tetracaine drop intervention 2: Lidocaine gel	1	Miami \| Florida \| United States \| -80.19366 \| 25.77427	11	0	0	0	NCT01383200	6TERMINATED	2011-10-01	2011-06-01	University of Miami	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	60	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	2MALE	false	The study will determine the effects of three doses of Androxal(enclomiphene citrate)on morning testosterone versus AndroGel(approved topical treatment)in men with low testosterone (\<350 ng/dL)after 6 weeks of continuous dosing.	Study will require 7 visits, which includes 2 overnight stays in a clinic. One visit is an eye exam. Blood samples are required at all visits including sampling every hour for a 24 hour time period during the 2 overnight stays. A six month extension study will be available for all subjects completing the 6-week study.	Secondary Hypogonadism		null	4	arm 1: Androxal 6.25 mg/day arm 2: Androxal 12.5 mg/day arm 3: Androxal 25 mg/day arm 4: AndroGel 5G topical testosterone	[ 0, 0, 0, 1 ]	2	[ 0, 0 ]	intervention 1: capsule oral 1X a day 6 weeks intervention 2: topical gel 1X a day 6 weeks	intervention 1: Androxal (enclomiphene citrate) intervention 2: Testosterone	2	Houston \| Texas \| United States \| -95.36327 \| 29.76328 San Antonio \| Texas \| United States \| -98.49363 \| 29.42412	60	0	0	0	NCT01386606	1COMPLETED	2011-10-01	2011-06-01	Repros Therapeutics Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	40	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	1FEMALE	false	This was a pilot study to observe patient satisfaction with BOTOX® Cosmetic treatment in glabellar rhytides (frown lines) using a new treatment satisfaction measure.	null	Glabellar Frown Lines		null	2	arm 1: Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0. arm 2: Normal Saline (placebo) injected into the glabellar region on Day 0.	[ 1, 2 ]	2	[ 2, 0 ]	intervention 1: botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0. intervention 2: Normal saline (placebo) injected into the glabellar region on Day 0.	intervention 1: botulinum toxin Type A intervention 2: normal saline (placebo)	1	East Chicago \| Illinois \| United States \| N/A \| N/A	39	0	0	0	NCT01391312	1COMPLETED	2011-10-01	2011-06-01	Allergan	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	436	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: * Strategy A = MeteoSpasmyl®, on-demand therapy * Strategy B = standard of care chosen by the physician	null	Irritable Bowel Syndrome		null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: best standard of care prescriptions intervention 2: on-demand therapy	intervention 1: anti spasmodic agents intervention 2: alverine citrate, simeticone	0	null	432	0	0	0	NCT01404923	1COMPLETED	2011-10-01	2009-12-01	Laboratoires Mayoly Spindler	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	575	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study will compare the nasal congestion symptom relief of phenylephrine extended release tablets and placebo in participants with allergic rhinitis.	null	Seasonal Allergic Rhinitis	Nasal Decongestants Rhinitis, Allergic, Seasonal Rhinitis Nose Conditions Respiratory Tract Diseases Phenylephrine	null	2	arm 1: None arm 2: None	[ 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days intervention 2: Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days intervention 3: Loratadine, 10 mg, once daily as rescue medication, only if needed ...	intervention 1: Phenylephrine intervention 2: Placebo intervention 3: Loratadine	0	null	575	0	0	0	NCT01413958	1COMPLETED	2011-10-01	2011-08-01	Bayer	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 2 ]	18	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	true	0ALL	false	This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.	null	Sickle Cell Disease		null	5	arm 1: A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion. arm 2: A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates. arm 3: A single 5-mg prasugrel ODT administere...	[ 1, 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Administered orally intervention 2: Administered orally	intervention 1: Prasugrel (clinical formulation) intervention 2: Prasugrel (Orally Disintegrating Tablet [ODT])	1	Honolulu \| Hawaii \| United States \| -157.85833 \| 21.30694	90	0	0	0	NCT01430091	1COMPLETED	2011-10-01	2011-09-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 0 ]	42	RANDOMIZED	SINGLE_GROUP	null	3TRIPLE	true	0ALL	false	SCUBA divers and chamber inside attendants will undergo a brief hyperbaric chamber excursion and will be asked to what chamber pressure they were compressed and what gas they breathed.	In clinical trials evaluating hyperbaric oxygen, blinding can be challenging. Options for participant blinding include offering regular air at a lower pressure than the hyperbaric oxygen intervention, or compressing all participants to the same pressure but providing different gas mixes to the active and sham arms. In...	Traumatic Brain Injury	Hyperbaric oxygen	null	4	arm 1: Sham Chamber Session Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion arm 2: Hyperbaric Oxygen (1.5 atm abs) Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion arm 3: Sham Chamber Session Altitude Equivalent 1.2 atm abs (5.1 psig...	[ 3, 0, 3, 0 ]	2	[ 0, 0 ]	intervention 1: Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs. intervention 2: Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs	intervention 1: Hyperbaric Oxygen (1.5 atm abs) intervention 2: Sham Chamber Session	2	Murray \| Utah \| United States \| -111.88799 \| 40.66689 Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	42	0	0	0	NCT01430325	1COMPLETED	2011-10-01	2011-07-01	Intermountain Health Care, Inc.	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	22	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	false	0ALL	true	The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.	null	Allergic Rhinitis Allergic Conjunctivitis		null	2	arm 1: Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16. arm 2: Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: two sprays in each nostril once daily intervention 2: two sprays in each nostril once daily	intervention 1: Fluticasone Propionate Nasal Spray intervention 2: Saline Nasal Spray	1	Andover \| Massachusetts \| United States \| -71.137 \| 42.65843	22	0	0	0	NCT01439815	1COMPLETED	2011-10-01	2011-09-01	ORA, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	30	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This study looks at the improvements in signs and symptoms in patients with inflammation of the lids, blepharitis, using two different FDA approved topical antibiotic agents, Besifloxocin and Erythromycin. It also evaluates the bacterial cultures in these patients for microbiologic evidence of improvement.	This is a pilot project involving thirty patients with a specific form of inflammtion of the lids called anterior blepharitis. The patients are graded for their signs a symptoms and then randomized to receive either topical Besifloxocin or Erythromycin in addition to standard lid hygiene measures. All patients have cul...	Blepharitis	blepharitis topical erythromycin topical besifloxocin	null	2	arm 1: Use of topical besifloxocin to treat acute blepharitis arm 2: Topical Erythromycin ointment for treatment of acute blepharitis	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: Topical erythromycin ointment twice a day intervention 2: Topical Besifloxocin twice a day	intervention 1: Erythromycin intervention 2: Besifloxocin	1	Louisville \| Kentucky \| United States \| -85.75941 \| 38.25424	30	0	0	0	NCT01478256	1COMPLETED	2011-10-01	2011-08-01	John, George, M.D.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	239	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Heartburn is the main symptom of Gastroesophageal Reflux Disease (GERD), which, accompanied by acid regurgitation and other symptoms, has a substantial negative impact on a patients' quality of life. Although a number of treatment options are available, a more effective therapy is still required. The failure of proton ...	null	Gastroesophageal Reflux		null	2	arm 1: Treatment of heartburn with Zegerid arm 2: Treatment of heartburn with Losec	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days. intervention 2: 20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.	intervention 1: Zegerid intervention 2: Losec	1	Warsaw \| N/A \| Poland \| 21.01178 \| 52.22977	239	0	0	0	NCT01493089	1COMPLETED	2011-10-01	2011-04-01	Norgine	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 0 ]	17	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	2MALE	false	"HIV lipodystrophy syndrome" (HLS) is characterized by loss of fat in the arms and legs, with increase in fat in the abdomen, and abnormal blood lipid levels. Persons with HLS have high risk for cardiovascular disease and diabetes mellitus and the metabolic syndrome. The investigators have previously shown that the abn...	The HIV lipodystrophy syndrome (HLS) is characterized by peripheral fat wasting and central obesity, and hyperlipidemia (mainly hypertriglyceridemia), which results in insulin resistance. HLS patients are at high risk for cardiovascular disease, diabetes mellitus and the metabolic syndrome. The investigators have prev...	HIV Lipodystrophy	lipid kinetics fat oxidation	null	2	arm 1: Each subject received 0.02 mg leptin / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg leptin / kg for two more months. arm 2: Each subject received placebo at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by a dose of 0.04 mg / kg ...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months. intervention 2: Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more ...	intervention 1: Human recombinant leptin ("metreleptin") intervention 2: Placebo	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	17	0	0	0	NCT01511016	1COMPLETED	2011-10-01	2003-02-01	Baylor College of Medicine	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 2 ]	35	NA	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	true	Study to evaluate the safety and tolerability of PRO-155 Ophthalmic Solution 0.09 % in healthy volunteers.	A phase I, open label and unicentric clinical trial to evaluate the safety and tolerability of PRO-155 Ophthalmic Solution 0.09 % in healthy volunteers.	Inflammation Cataract	PRO-155 Ocular NSAIDs Safety and tolerability Ocular Inflammation Ocular Paint	null	1	arm 1: Drug: Bromfenac ophthalmic solution 1 drop 4 times per day	[ 0 ]	1	[ 0 ]	intervention 1: Drug: Bromfenac Other names: PRO-155	intervention 1: Bromfenac	1	Guadalajara \| Jalisco \| Mexico \| -103.34749 \| 20.67738	35	0	0	0	NCT01535443	1COMPLETED	2011-10-01	2011-09-01	Laboratorios Sophia S.A de C.V.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 0 ]	1	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Hyperuricemia (high uric acid level) has been correlated to hypertension (high blood pressure) and overall cardiovascular disease risk in several studies. The relationship has even been noted to be independent of metabolic syndrome and kidney function. It has been repeatedly noted that hyperuricemia was an independent ...	Screening and Recruitment * Identify and recruit 20 participants from the University of Mississippi Medical Center General Internal Medicine/Hypertension and Family Medicine Clinics. * Participants must be currently taking allopurinol for the treatment of gout and be on a stable dose of allopurinol for at least 2 mont...	Blood Pressure Gout	Blood Pressure Gout allopurinol febuxostat uric acid	null	1	arm 1: Patients currently treated with allopurinol will be switched to febuxostat, and the blood pressure differences between the two arms will be compared.	[ 0 ]	1	[ 0 ]	intervention 1: If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily. If baseline allopurinol dose \> 300 mg daily, will initiate febuxostat 80 mg daily. Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at base...	intervention 1: febuxostat	1	Jackson \| Mississippi \| United States \| -90.18481 \| 32.29876	1	0	0	0	NCT01701622	6TERMINATED	2011-10-01	2010-01-01	University of Mississippi Medical Center	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	13	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This study investigates whether milnacipran reduces radicular pain ("sciatica") in patients with lumbosacral disc disease.	The current study evaluates the potential efficacy of milnacipran in reducing lower extremity radicular pain associated with lumbar disk disease. Milnacipran will be titrated based on efficacy and tolerability aimed at the higher end of the therapeutic range; a recent study of a serotonin norepinephrine reuptake inhibi...	Radicular Pain Related to Lumbosacral Disc Disease	sciatica radiculopathy lumbar disc lumbosacral disc	null	2	arm 1: Milnacipran, flexibly dosed arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: Milnacipran intervention 2: Placebo	0	null	11	0	0	0	NCT01777581	1COMPLETED	2011-10-01	2010-03-01	Duke University	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 0 ]	37	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	true	The purpose of this study was to investigate the effects of three different glycemic treatment conditions (tight, conventional, and standard) in the intraoperative period on: 1) postoperative surgical site infections, and 2) postoperative procalcitonin, and C-reactive protein levels in patients undergoing open-heart su...	An experimental design with a multilevel, single factor, within-subjects design was utilized. Patients were nested within anesthesia provider teams. The design was counterbalanced by means of a Latin square, where each of three anesthesia provider teams dispensed each of three glycemic treatment conditions once.	Diabetes Hyperglycemia Surgical Site Infection	Glycemic control	null	3	arm 1: The tight glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial bolus of insulin and insulin infusion was initiated prior to induction of anesthesia if t...	[ 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline. intervention 2: The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline. intervention 3: Insulin was Regular Insulin administered intravenous bolus.	intervention 1: Tight Glycemic intervention 2: Conventional Glycemic intervention 3: Standard Glycemic	1	Tampa \| Florida \| United States \| -82.45843 \| 27.94752	37	0	0	0	NCT01831154	1COMPLETED	2011-10-01	2010-05-01	James A. Haley Veterans Administration Hospital	1FED	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	3	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This phase II trial studies how well giving bortezomib, lenalidomide, and dexamethasone together works in treating patients with multiple myeloma undergoing stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalido...	CONSOLIDATION: Patients receive bortezomib, lenalidomide, and dexamethasone (VLD) therapy comprising bortezomib intravenously (IV) on days 1, 4, 8, and 11, lenalidomide orally (PO) once daily (QD) on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat ever...	Refractory Plasma Cell Myeloma		null	1	arm 1: CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity. I...	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: Given IV intervention 2: Given PO intervention 3: Given PO or IV	intervention 1: Bortezomib intervention 2: Lenalidomide intervention 3: Dexamethasone	1	Aurora \| Colorado \| United States \| -104.83192 \| 39.72943	3	0	0	0	NCT02353468	6TERMINATED	2011-10-01	2009-12-01	University of Colorado, Denver	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	51	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	Comparison of two different regimens of analgesia after inguinal hernia repair. First, is a classical intravenous protocol with paracetamol and tramadol. Second is an oral protocol with Zaldiar (combination of paracetamol and tramadol).	Comparison of two different regimens of analgesia after inguinal hernia repair. First, is a classical intravenous protocol with paracetamol and tramadol. This is the classical approach. Second is an oral protocol with Zaldiar (combination of paracetamol and tramadol). This is the new approach.	Pain		null	2	arm 1: Postoperative Analgesia with Zaldiar arm 2: Postoperative Analgesia with Paracetamol-Tramadol	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol) intervention 2: Postoperative analgesia with intravenous Paracetamol and Tramadol	intervention 1: Zaldiar intervention 2: Paracetamol-Tramadol	0	null	51	0	0	0	NCT02389361	1COMPLETED	2011-10-01	2011-04-01	Astes	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	40	NA	SINGLE_GROUP	1PREVENTION	0NONE	false	0ALL	false	Postoperative nausea and vomiting (PONV) is a displeasing experience that distresses surgical patients during the first 24 hours after a surgical procedure. The incidence of postoperative nausea occurs in about 50%, the incidence of postoperative vomiting is about 30%, and in high-risk patients, the PONV rate could be ...	At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis. After surgery, subjects were transferred to the surgical intensive care unit (SICU) or post anesthesia care unit as clinically indicated. Ondansetron 4 mg IV was admi...	Postoperative Nausea and Vomiting	Palonosetron Craniotomy Nausea Vomiting	null	1	arm 1: At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis. intervention 2: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis. intervention 3: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.	intervention 1: Palonosetron 0.075 mg IV intervention 2: Dexamethasone 10 mg IV intervention 3: Promethazine 25 mg IV	0	null	40	0	0	0	NCT02635828	1COMPLETED	2011-10-01	2009-10-01	Ohio State University	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	32	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	false	Thirty-two subjects diagnosed with COPD were enrolled, received each study treatment and completed the follow-up assessments. During each of the four study periods, subjects were admitted to the clinic on Day -1 and housed overnight until after the last spirometry measurement. Serial pulmonary function tests were perfo...	Subjects were assigned to one of the 4-treatment sequence groups presented in the table above according to a randomization schedule supplied by the Sponsor before study initiation. The randomization scheme did not include assignments for replacement subjects. Subjects reported to their respective clinical research uni...	Chronic Obstructive Pulmonary Disease, COPD	Chronic Obstructive Pulmonary Disease, COPD	null	4	arm 1: Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg arm 2: Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg arm 3: Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD...	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None intervention 4: None	intervention 1: Placebo intervention 2: TD-4208 700 μg intervention 3: TD-4208 350 μg intervention 4: Ipratropium 500 μg	1	Wellington \| N/A \| New Zealand \| 174.77557 \| -41.28664	128	0	0	0	NCT03064113	1COMPLETED	2011-10-01	2011-05-01	Mylan Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	111	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find ...	PRIMARY OBJECTIVES: I. To assess the progression-free survival of patients receiving 131 I labeled tositumomab antibody, etoposide (VP-16) and cyclophosphamide (CY) followed by autologous transplantation. II. To examine the potential efficacy of 131 I labeled tositumomab antibody, etoposide (VP-16) and cyclophosphami...	Anaplastic Large Cell Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult ...		null	1	arm 1: RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4. CHEMOTHERAPY: Patients receive...	[ 0 ]	5	[ 0, 0, 4, 3, 3 ]	intervention 1: Given IV intervention 2: Given IV intervention 3: Given IV intervention 4: Ancillary study intervention 5: Undergo ASCT given via central catheter	intervention 1: cyclophosphamide intervention 2: etoposide intervention 3: iodine I 131 tositumomab intervention 4: quality-of-life assessment intervention 5: peripheral blood stem cell transplantation	1	Seattle \| Washington \| United States \| -122.33207 \| 47.60621	107	0	0	0	NCT00073918	1COMPLETED	2011-10-02	1999-02-01	Fred Hutchinson Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 2 ]	30	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	true	0ALL	null	Drug interaction study evaluating the pharmacokinetic profiles of Metronidazole administered alone \& in combination with MMX® Mesalazine/mesalamine	null	Healthy		null	2	arm 1: None arm 2: None	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally intervention 2: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 day...	intervention 1: Metronidazole + MMX Mesalazine/mesalamine placebo intervention 2: Metronidazole + MMX Mesalazine/mesalamine	1	Lenexa \| Kansas \| United States \| -94.73357 \| 38.95362	58	0	0	0	NCT01418365	1COMPLETED	2011-10-05	2011-08-22	Shire	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	55	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas aeruginosa (P. aeruginosa) at enrollment into CTBM100C2303.	null	Pseudomonas Aeruginosa Cystic Fibrosis	Tobramycin Inhalation Powder Cystic fibrosis Lung diseases Anti-Bacterial Agents	null	1	arm 1: Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.	[ 0 ]	1	[ 0 ]	intervention 1: Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.	intervention 1: Tobramycin inhalation powder	2	Tallinn \| N/A \| Estonia \| 24.75353 \| 59.43696 Yaroslavl \| N/A \| Russia \| 39.87368 \| 57.62987	55	0	0	0	NCT00982930	1COMPLETED	2011-10-06	2009-08-12	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	700	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	1FEMALE	false	To evaluate the efficacy, dose response and safety of four doses of GSK2190915 in tablet form (10mg, 30mg, 100mg and 300mg) administered once daily, over 8 weeks compared with placebo in adolescent and adult subjects (12 years of age and older) with persistent asthma. These data will form the basis for the selection of...	null	Asthma	Efficacy Asthma Safety Fluticasone Propionate FLAP Beta-agonists GSK2190915 Montelukast Placebo FLAIR	null	7	arm 1: GSK2190915 10mg (1 x 10mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS arm 2: GSK2190915 30mg (1 x 30mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled p...	[ 0, 0, 0, 0, 1, 1, 2 ]	10	[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS intervention 2: GSK2190915 100mg (1 x 100mg) once daily in the morning intervention 3: GSK2190915 10mg (1 x 10mg) once daily in the morning intervention 4: GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning interventio...	intervention 1: Fluticasone Propionate 100mcg via ACCUHALER/DISKUS intervention 2: GSK2190915 100mg intervention 3: GSK2190915 10mg intervention 4: GSK2190915 300mg intervention 5: GSK2190915 30mg intervention 6: Montelukast 10mg intervention 7: Placebo GSK2190915 one tablet intervention 8: Placebo montelukast interven...	84	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Newport Beach \| California \| United States \| -117.92895 \| 33.61891 San Diego \| California \| United States \| -117.16472 \| 32.71571 Tallahassee \| Florida \| United States \| -84.28073 \| 30.43826 ...	700	0	0	0	NCT01147744	1COMPLETED	2011-10-06	2010-06-28	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	17	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with recurrent or advanced transitional cell carcinoma of the bladder. The combination of Oxaliplatin and Gemcitabine is considered investigational and this study will help in determining if their activity and toxicity profiles are comp...	The combination of Oxaliplatin and Gemcitabine has synergistic effects on a variety of human cancer cell lines in vitro. Clinically, it has demonstrated activity in other malignancies including lung, and pancreas. In the former study, poor prognosis advanced non-small cell lung cancer patients received Gemcitabine 1000...	Carcinoma, Transitional Cell	Carcinoma, Transitional Cell Bladder Cancer oxaliplatin Gemcitabine	null	1	arm 1: Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.	[ 0 ]	1	[ 0 ]	intervention 1: Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.	intervention 1: Oxaliplatin with Gemcitabine	1	Orange \| California \| United States \| -117.85311 \| 33.78779	17	0	0	0	NCT04039867	6TERMINATED	2011-10-06	2005-01-20	University of California, Irvine	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	130	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient will know what treatment is ...	null	Crohn's Disease	Ileal Crohn's Disease Ileo-colonic Crohn's Disease Colonic Chron's Disease	null	4	arm 1: Participants received placebo intravenously at baseline and week 4. arm 2: Participants received 210 mg brodalumab intravenously at baseline and week 4. arm 3: Participants received 350 mg brodalumab intravenously at baseline and week 4. arm 4: Participants received 700 mg brodalumab intravenously at baseline an...	[ 2, 0, 0, 0 ]	2	[ 2, 0 ]	intervention 1: Administered as as an intravenous (IV) infusion over at least 30 minutes. intervention 2: Administered as as an intravenous (IV) infusion over at least 30 minutes.	intervention 1: Brodalumab intervention 2: Placebo	50	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Dothan \| Alabama \| United States \| -85.39049 \| 31.22323 Lowell \| Arkansas \| United States \| -94.13076 \| 36.25535 Jacksonville \| Florida \| United States \| -81.65565 \| 30.33218 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Hammond \| Louisiana \| United S...	128	0	0	0	NCT01150890	6TERMINATED	2011-10-15	2010-11-09	Amgen	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 2 ]	24	NA	SINGLE_GROUP	7BASIC_SCIENCE	0NONE	true	0ALL	false	Characterize and assess PK of guaifenesin in Mucinex® 1200 mg ER Bi-Layer Tablet	A Phase I, Open-Label, Single-Dose, Single Period Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Bi-Layer Tablet in Normal Healthy Subjects	Healthy Subjects		null	1	arm 1: Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)	[ 0 ]	1	[ 0 ]	intervention 1: Mucinex® 1200 mg ER Bi-Layer tablet	intervention 1: Mucinex®	0	null	24	0	0	0	NCT03633487	1COMPLETED	2011-10-15	2011-10-11	Reckitt Benckiser LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	1,635	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)	null	Pulmonary Disease, Chronic Obstructive	Safety COPD FEV1 Efficacy	null	4	arm 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 2: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 3: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 4: Long Acting Beta Agonist(LABA)	[ 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD intervention 2: Long Acting Beta Agonist(LABA) Inhalation Powder	intervention 1: FF/GW642444 Inhalation Powder intervention 2: GW642444 Inhalation Powder	183	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Ozark \| Alabama \| United States \| -85.64049 \| 31.45906 Tallassee \| Alabama \| United States \| -85.89329 \| 32.53597 Chandler \| Arizona \| United St...	1,633	0	0	0	NCT01017952	1COMPLETED	2011-10-17	2009-09-25	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	19	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of this study is to examine the effectiveness of vitamin D3 versus vitamin D2 in raising vitamin D levels and suppressing parathyroid hormone levels in patients with kidney disease who are not on dialysis.	Subjects will be randomized and assigned to one of the treatment groups (D2 or D3). Subjects will be dispensed a supply of 1.25 mg cholecalciferol/ergocalciferol tablets, depending on their randomization outcome. The number of pills dispensed and medication instructions will be determined by their 25OHD level and K/DOQ...	Chronic Kidney Disease Stage 3 and 4	CKD Vitamin D	null	2	arm 1: Patients randomized to take vitamin D2 arm 2: Patient's randomized to take Vitamin D3	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: 1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months intervention 2: 1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months	intervention 1: Ergocalciferol intervention 2: Cholecalciferol	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	19	0	0	0	NCT01173848	6TERMINATED	2011-10-18	2010-07-01	The Cleveland Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	612	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period...	null	Asthma	GW642444 Vilanterol Asthma Fluticasone Furoate	null	3	arm 1: Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks arm 2: Fluticasone furoate inhalation powder once daily for 12 weeks arm 3: Placebo inhalation powder once daily for 12 weeks	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks intervention 2: Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks intervention 3: Placebo Inhaltion Powder inhaled orally once daily for 12 weeks	intervention 1: Fluticasone furoate/Vilanterol Inhalation Powder intervention 2: Fluticasone Furoate Inhalation Powder intervention 3: Placebo Inhaltion Powder	70	Bell Gardens \| California \| United States \| -118.15146 \| 33.96529 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Long Beach \| California \| United States \| -118.18923 \| 33.76696 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Newport Beach \| California \| United States \| -117.92895 ...	609	0	0	0	NCT01165138	1COMPLETED	2011-10-19	2010-08-20	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	-0
[ 4 ]	528	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol 100/25mcg once daily compared with Salmeterol/Fluticasone Propionate 50/500mcg twice daily over a 12-week treatmen period in subjects with COPD.	This is a randomized, double-blind, double-dummy, multi-centre parallel group study. Subjects who meet the eligilibilty criteria at Screening and meet the randomization criteria at the end of a 2-week Run-In period will enter a 12-week Treatment period. There will be a 7-day Follow-up period after the treatment period.	Pulmonary Disease, Chronic Obstructive		null	2	arm 1: Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA) arm 2: Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Inhalation Powder intervention 2: Inhalation Powder	intervention 1: Fluticasone Furoate 100mcg/Vilanterol 25mcg intervention 2: Fluticaosne Propionate 500mcg/Salmeterol 50mcg	66	Bouge \| N/A \| Belgium \| 4.89218 \| 50.47193 Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045 Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045 Edegem \| N/A \| Belgium \| 4.44504 \| 51.15662 Genk \| N/A \| Belgium \| 5.50082 \| 50.965 Ghent \| N/A \| Belgium \| 3.71667 \| 51.05 Gilly \| N/A \| Belgium \| 4.4789 \| 50.42449 Béthune \| N/A \| Fra...	528	0	0	0	NCT01342913	1COMPLETED	2011-10-19	2011-02-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	276	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months	null	ADHD		null	2	arm 1: Open-label 30, 50, or 70mg arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods) intervention 2: Placebo capsule once per day (double-blind period)	intervention 1: Lisdexamfetamine dimesylate (LDX) intervention 2: Placebo	51	Rolling Hills Estates \| California \| United States \| -118.35813 \| 33.78779 South Miami \| Florida \| United States \| -80.29338 \| 25.7076 Overland Park \| Kansas \| United States \| -94.67079 \| 38.98223 Memphis \| Tennessee \| United States \| -90.04898 \| 35.14953 Hoboken \| Antwerpen \| Belgium \| 4.34844 \| 51.17611 Leuven \| Flem...	433	6	0.013857	1	NCT00784654	1COMPLETED	2011-10-26	2009-01-27	Shire	4INDUSTRY	false	false	false	null	5	0	0	0	0	0	1	0.006366
[ 4 ]	687	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The current trial is designed to prospectively explore the safety of erythropoietin use for the treatment of anemia during boceprevir plus peginterferon alfa-2b/Ribavirin (PEG2b/RBV) therapy and to assess its relationship to efficacy. All participants in this trial will be treated with the triple combination of bocepre...	null	Hepatitis C, Chronic		null	3	arm 1: Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained \>10 g/dL throughout the 28- or 48-week treatment period. arm 2: After the initiati...	[ 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 800 mg given three times a day (TID), orally (PO) intervention 2: 1.5 µg/kg/week given subcutaneously (SC) intervention 3: Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO) intervention 4: Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW),...	intervention 1: Boceprevir intervention 2: Peginterferon alfa-2b (PEG2b) intervention 3: Ribavirin (RBV) intervention 4: Erythropoietin	0	null	687	6	0.008734	1	NCT01023035	1COMPLETED	2011-10-26	2009-12-07	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	1	0	0	0	1	4	0	0.004009
[ 3 ]	213	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	A phase 2, multicenter, uncontrolled, open-label trial in participants with Multi-drug Resistant Tuberculosis (MDR-TB). Only participants who completed Trial 242-07-204 (NCT00685360) were eligible. The trial was performed globally at 14 sites qualified to treat MDR-TB. All 434 participants who completed Trial 242-07-20...	null	Tuberculosis, Multidrug-Resistant		null	2	arm 1: Participants received Delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) along with at least 4 additional anti-TB medications per optimized background regimen (OBR) from Week 0 to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening. intervention 2: Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistan...	intervention 1: Delamanid intervention 2: OBR	8	Beijing \| N/A \| China \| 116.39723 \| 39.9075 Tallinn \| N/A \| Estonia \| 24.75353 \| 59.43696 Tartu \| N/A \| Estonia \| 26.72509 \| 58.38062 Riga \| N/A \| Latvia \| 24.10589 \| 56.946 Lima \| N/A \| Peru \| -77.02824 \| -12.04318 Makati City \| N/A \| Philippines \| 121.03269 \| 14.55027 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566 Seo...	213	1	0.004695	1	NCT02573350	1COMPLETED	2011-10-27	2009-03-26	Otsuka Pharmaceutical Development & Commercialization, Inc.	4INDUSTRY	false	false	false	null	0	0	0	1	0	0	0	0.000829
[ 3 ]	163	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD). Treatment with doses of GSK573719 dosed twice daily will also be included to further evaluate dosing frequency. Treat...	Inhaled bronchodilators, such as beta 2 agonists and anticholinergics, and inhaled corticosteroids are the mainstays of therapy in patients diagnosed with COPD. Anticholinergic bronchodilators or long acting muscarinic receptor antagonists function by blocking endogenous airway smooth muscle cholinergic tone. Treatment...	Pulmonary Disease, Chronic Obstructive	Long acting muscarinic antagonist Tiotropium Chronic Bronchitis Emphysema Chronic Obstructive Pulmonary Disease	null	3	arm 1: 18 mcg, inhaled long acting muscarinic antagonist arm 2: inhaled medication arm 3: inactive/excipients only	[ 1, 0, 2 ]	8	[ 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: 125 mcg once daily intervention 2: 62.5 mcg once daily intervention 3: 31.25 mcg once daily intervention 4: 15.6 mcg once daily intervention 5: 31.25 mcg twice daily intervention 6: 15.6 mcg twice daily intervention 7: 18 mcg once daily intervention 8: once or twice daily	intervention 1: GSK573719 intervention 2: GSK573719 intervention 3: GSK573719 intervention 4: GSK573719 intervention 5: GSK573719 intervention 6: GSK573719 intervention 7: Tiotropium intervention 8: Placebo	13	Costa Mesa \| California \| United States \| -117.91867 \| 33.64113 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Duluth \| Georgia \| United States \| -84.14464 \| 34.00288 Edina \| Minnesota \| United States \| -93.34995 \| 44.88969 Charlotte \| North Carolina \| United States \| -80.84313 \| 35.22709 Raleigh \| North Caroli...	466	0	0	0	NCT01372410	1COMPLETED	2011-10-27	2011-07-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	33	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial hypertension who completed FUTURE 1 study.	null	Pulmonary Arterial Hypertension	bosentan pulmonary arterial hypertension children FUTURE 1	null	1	arm 1: Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.	[ 0 ]	1	[ 0 ]	intervention 1: 32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally	intervention 1: Bosentan	0	null	72	0	0	0	NCT00319020	1COMPLETED	2011-10-28	2005-08-23	Actelion	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	1,626	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)	null	Pulmonary Disease, Chronic Obstructive	COPD Safety FEV1 Efficacy	null	4	arm 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 2: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 3: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 4: Long Acting Beta Agonist(LABA)	[ 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD intervention 2: Long Acting Beta Agonist(LABA) Inhalation Powder via DPI	intervention 1: FF/GW642444 Inhalation Powder intervention 2: GW642444 Inhalation Powder	188	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Jasper \| Alabama \| United States \| -87.27751 \| 33.83122 Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Phoenix \| Arizona \| United Sta...	1,622	0	0	0	NCT01009463	1COMPLETED	2011-10-31	2009-09-25	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	214	RANDOMIZED	SINGLE_GROUP	0TREATMENT	2DOUBLE	false	0ALL	null	The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA)...	null	Juvenile Rheumatoid Arthritis	Juvenile Idiopathic Arthritis	null	3	arm 1: Double Blind Period arm 2: Double Blind Period arm 3: None	[ 1, 2, 0 ]	3	[ 0, 0, 0 ]	intervention 1: IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier). intervention 2: IV infusions, IV, N/A, every 4 weeks, 6 months. intervention 3: Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for s...	intervention 1: Abatacept intervention 2: Placebo intervention 3: Abatacept	36	Omaha \| Nebraska \| United States \| -95.94043 \| 41.25626 Livingston \| New Jersey \| United States \| -74.31487 \| 40.79593 New Hyde Park \| New York \| United States \| -73.68791 \| 40.7351 Valhalla \| New York \| United States \| -73.77513 \| 41.07482 Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711 Cleveland \| Ohio \| Uni...	190	1	0.005263	1	NCT00095173	1COMPLETED	2011-11-01	2003-12-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0	0	0	0	0	1	0	0.00093
[ 4 ]	1,068	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients after 48 weeks of treatment. Secondary objectives are to evaluate safety and pharmacokinetics...	null	HIV Infections		null	2	arm 1: 400 mg QD arm 2: 200 mg BID	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 200 mg BID intervention 2: 400 mg QD	intervention 1: nevirapine IR intervention 2: nevirapine XR	202	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Bakersfield \| California \| United States \| -119.01871 \| 35.37329 Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Bev...	2,394	2	0.000835	1	NCT00561925	1COMPLETED	2011-11-01	2007-11-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0	0	0	1	0	1	0	0.000229
[ 3 ]	107	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to determine efficacy of treatment with bortezomib (in combination with doxorubicin and dexamethasone) in previously untreated patients with Multiple Myeloma.	This is an open-label, single-arm, multicentre study which will enroll approximately 105 patients. Open-label means all people involved in the study know the identity of the intervention. Single-arm means there is one group of patients, all receiving the same treatment. Four 21-day cycles of a combination of bortezomib...	Multiple Myeloma	Multiple Myeloma transplant eligible doxorubicin dexamethasone bortezomib bortezomib resistance PAD induction PIMMS Trial	null	1	arm 1: PAD induction Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1 4 8 \& 11) Doxorubicin 20 mg/m2 i.v. (D1 \& 4) Dexamethasone 20 mg p.o. (D1 2 4 5 8 9 11 \& 12)	[ 0 ]	1	[ 0 ]	intervention 1: Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)	intervention 1: PAD induction	16	Adelaide \| N/A \| Australia \| 138.59863 \| -34.92866 Box Hill \| N/A \| Australia \| 145.12545 \| -37.81887 Brisbane \| N/A \| Australia \| 153.02809 \| -27.46794 Camperdown \| N/A \| Australia \| 151.17642 \| -33.88965 Geelong \| N/A \| Australia \| 144.36069 \| -38.14711 Gosford \| N/A \| Australia \| 151.34399 \| -33.4244 Greenslopes \| N...	214	2	0.009346	1	NCT00872521	1COMPLETED	2011-11-01	2009-01-01	Janssen-Cilag Pty Ltd	4INDUSTRY	false	false	false	null	0	0	0	0	0	2	0	0.002567
[ 2 ]	99	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	true	2MALE	true	To determine the number of men who have suppression of sperm production when using a daily regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel applied transdermally.	null	Contraception	Contraception Male Contraception Suppression of Sperm Production	null	3	arm 1: Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head. arm 2: Two ...	[ 2, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily. intervention 2: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nest...	intervention 1: Testosterone intervention 2: Nestorone® intervention 3: Nestorone® intervention 4: Nestorone®	2	Torrance \| California \| United States \| -118.34063 \| 33.83585 Seattle \| Washington \| United States \| -122.33207 \| 47.60621	99	1	0.010101	1	NCT00891228	1COMPLETED	2011-11-01	2009-05-01	Health Decisions	7OTHER	false	false	false	null	0	1	0	0	0	0	0	0.001785
[ 3 ]	616	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	Neutrophils are thought to play an important role in the pathophysiology of chronic obstructive pulmonary disease (COPD). Navarixin (SCH 527123, MK-7123) is an antagonist of the cysteine-X-cysteine chemokine receptor 2 (CXCR2) and is thought to reduce neutrophil migration to the diseased lung. It is theorized that redu...	null	COPD		null	4	arm 1: Participants receive navarixin 10 mg, as one navarixin 10 mg capsule and two placebo capsules, administered orally once daily (QD) for up to 2 years arm 2: Participants receive navarixin 30 mg, as one navarixin 30 mg capsule and two placebo capsules, administered orally QD for up to 2 years arm 3: Participants r...	[ 0, 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Navarixin 10 mg and 30 mg capsules intervention 2: Placebo to navarixin capsules intervention 3: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic	intervention 1: Navarixin intervention 2: Placebo intervention 3: Rescue medication	0	null	614	20	0.032573	1	NCT01006616	6TERMINATED	2011-11-01	2009-10-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	20	0	0.021184
[ 3 ]	4	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Sildenafil is efficacious in newborns with persistent pulmonary hypertension and its use will reduce the need for inhaled nitric oxide.	Letter to investigator dated 18 June 2012 that study was to be terminated. Study terminated due to evolved and widespread use of standard of care, relevance of study questioned. No safety reasons or issues.	PPHN Persistent Pulmonary Hypertension of the Newborn Hypoxic Respiratory Failure	PPHN neonates sildanefil IV	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but wi...	intervention 1: sildanefil	1	London \| N/A \| United Kingdom \| -0.12574 \| 51.50853	4	1	0.25	1	NCT01069861	6TERMINATED	2011-11-01	2010-12-01	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	4INDUSTRY	false	false	false	null	0	0	1	0	0	0	0	0.045587
[ 4 ]	224	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This study will compare the efficacy and safety of re-treatment with 2 doses of MabThera (rituximab) in patients with active rheumatoid arthritis (RA) who have previously experienced an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapies etanercept, infliximab or adalimumab therapy. Al...	null	Rheumatoid Arthritis		null	2	arm 1: 1000 mg IV rituximab arm 2: 2 x 1000 mg IV rituximab	[ 0, 0 ]	1	[ 0 ]	intervention 1: Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months	intervention 1: rituximab	53	Abbeville \| N/A \| France \| 1.83547 \| 50.10521 Agen \| N/A \| France \| 0.62055 \| 44.20199 Aix-en-Provence \| N/A \| France \| 5.44973 \| 43.5283 Aix-les-Bains \| N/A \| France \| 5.90863 \| 45.69173 Amiens \| N/A \| France \| 2.3 \| 49.9 Belfort \| N/A \| France \| 6.85385 \| 47.64218 Berck \| N/A \| France \| 1.6 \| 50.4 Bobigny \| N/A \| Fra...	215	1	0.004651	1	NCT01126541	1COMPLETED	2011-11-01	2006-09-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	1	0	0	0	0	0	0	0.000822
[ 3 ]	105	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Background: * Combined therapy with rituximab and fludarabine is the treatment of choice for advanced stage chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). * A new technology called deoxyribonucleic acid (DNA) microarray can be used to gain knowledge about the genetic basis of CLL/SLL. * Genetic stu...	Background: * Due to their synergistic action and non-overlapping toxicity profiles, the combination of Rituximab and Fludarabine is the treatment of choice for advanced stage chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL). * As such, we have designed this protocol to better understand the genetic...	Chronic Lymphocytic Leukemia	Genetics Bone Marrow Transplantation Immunosuppression T Lymphocytes Marrow Purging	null	2	arm 1: Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered. Eligible to donate cells. arm 2: Previously untreated intermediate or high risk B-cell chronic lymphocytic lym...	[ 0, 0 ]	3	[ 2, 0, 10 ]	intervention 1: Rituxan intervention 2: Fludara intervention 3: Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate b...	intervention 1: Rituximab intervention 2: Fludarabine phosphate intervention 3: Leukemic or stroma cells	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	49	0	0	0	NCT00001586	1COMPLETED	2011-11-01	1997-09-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	619	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	false	2MALE	true	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of selenium may be an effective way to prevent prostate cancer in patients who have neoplasia of the prostate. PURPOSE: Randomized phase III trial to study the effectiveness of selenium in preventing pro...	OBJECTIVES: * Compare the effects of selenium versus placebo on the 3-year incidence rate of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. * Compare the toxicity of these regimens in these patients. * Compare the effects of these regimens on the rate of increase in prostate-specific ...	Precancerous/Nonmalignant Condition Prostate Cancer	prostate cancer high grade prostatic intraepithelial neoplasia	null	2	arm 1: L-selenomethionine (Selenium)one tablet by mouth daily for 3 years. arm 2: L-selenomethionine placebo one tablet by mouth daily for 3 years	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Randomization between active L-selenomethionine and placebo intervention 2: Randomization between active L-selenomethionine and placebo	intervention 1: L-selenomethionine intervention 2: L-selenomethionine placebo	0	null	405	0	0	0	NCT00030901	1COMPLETED	2011-11-01	2000-02-01	SWOG Cancer Research Network	5NETWORK	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	2,026	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	null	The many benefits of breastfeeding are well documented. However, because of the risk of mother-to-child transmission (MTCT) of HIV from an HIV infected mother to her infant, there is considerable concern over the practice, especially in developing countries. The purpose of this study is to determine the safety and effe...	Breastfeeding provides general health, growth, and development benefits to an infant and significantly decreases the risk of certain acute and chronic diseases. Breastfeeding also decreases financial burden on the mother by decreasing the need for infant formula and health care for the infant. However, clinical evidenc...	HIV Infections	HIV Seronegativity Treatment Experienced Treatment Naive	null	2	arm 1: For infants: extended treatment with NVP arm 2: For infants: extended treatment with NVP placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study. intervention 2: Oral suspension taken once daily up to 6 months of age	intervention 1: Nevirapine intervention 2: Nevirapine placebo	5	Umlazi \| KwaZulu-Natal \| South Africa \| 30.88333 \| -29.96667 Dar es Salaam \| N/A \| Tanzania \| 39.26951 \| -6.82349 Kampala \| Mpigi \| Uganda \| 32.58219 \| 0.31628 Chitungwiza \| N/A \| Zimbabwe \| 31.07555 \| -18.01274 Chitungwiza \| N/A \| Zimbabwe \| 31.07555 \| -18.01274	1,519	0	0	0	NCT00074412	1COMPLETED	2011-11-01	2007-01-01	National Institute of Allergy and Infectious Diseases (NIAID)	0NIH	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	484	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	true	HIV infected pregnant women may take single-dose nevirapine (SD NVP) prior to giving birth to prevent mother-to-child transmission (MTCT) of HIV. However, SD NVP may cause NVP resistance in the mother, potentially ruling out some treatment options in the future. The purpose of this study is to determine which of three ...	A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to other nonnucleoside reverse transcriptase inhibitors (NNRTI) in the mother; as a result, future treatment options may be limited for these HIV infected women. The purpose of the study is to det...	HIV Infections	Treatment Naive	null	6	arm 1: SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV. arm 2: SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV. arm 3: SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF. arm 4: SD NVP and FTC/TDF provided at onset...	[ 0, 0, 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 200mg/300mg as one tablet taken orally once daily intervention 2: 150mg/300mg as one tablet taken orally twice daily intervention 3: 133.3mg/33.3mg as three capsules taken orally twice daily intervention 4: one 200 mg tablet taken orally	intervention 1: Emtricitabine/Tenofovir Disoproxil Fumarate intervention 2: Lamivudine/Zidovudine intervention 3: Lopinavir/Ritonavir intervention 4: single dose Nevirapine	8	Port-au-Prince \| N/A \| Haiti \| -72.33881 \| 18.54349 Pune \| Maharashtra \| India \| 73.85535 \| 18.51957 Chennai \| Tamil Nadu \| India \| 80.27847 \| 13.08784 Blantyre \| N/A \| Malawi \| 35.00854 \| -15.78499 Johannesburg \| Gauteng \| South Africa \| 28.04363 \| -26.20227 Westville \| KwaZulu-Natal \| South Africa \| 30.937 \| -29.8255...	422	0	0	0	NCT00099632	1COMPLETED	2011-11-01	2006-03-01	National Institute of Allergy and Infectious Diseases (NIAID)	0NIH	false	false	false	null	0	0	0	0	0	0	0	-0
[ 3 ]	71	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This randomized phase II trial is studying bortezomib and irinotecan to see how well they work compared to bortezomib alone in treating patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cel...	PRIMARY OBJECTIVES: I. To evaluate the activity of combination of PS-341 (bortezomib) and irinotecan in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) and the response rate of single agent PS-341 (followed by irinotecan at time of progression). SECONDARY O...	Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Si...		null	2	arm 1: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity arm 2: Patients receive bortezomib as in arm I. Courses repeat every 21 days in the absence of dis...	[ 0, 0 ]	3	[ 0, 0, 10 ]	intervention 1: Given IV intervention 2: Given IV intervention 3: Optional correlative studies	intervention 1: bortezomib intervention 2: irinotecan hydrochloride intervention 3: laboratory biomarker analysis	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	75	0	0	0	NCT00103259	1COMPLETED	2011-11-01	2005-07-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	20	RANDOMIZED	PARALLEL	null	1SINGLE	false	0ALL	true	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.	Presently some 4.5 million people are afflicted with Alzheimer's disease in the United States. At present pharmacologic treatment, although beneficial, is not curative. Certain nonpharmacologic treatments have assisted caregivers of AD patients by reducing their stress and burden, and others have aided patients, by imp...	Alzheimer's Disease	Alzheimer's disease caregiver training caregiver counseling individualized management memantine dementia	null	2	arm 1: Individualized Management including caregiver training and Memantine arm 2: Only Memantine	[ 0, 1 ]	2	[ 5, 0 ]	intervention 1: Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns. interventio...	intervention 1: Individualized management of AD including caregiver training intervention 2: Memantine	1	New York \| New York \| United States \| -74.00597 \| 40.71427	20	0	0	0	NCT00120874	1COMPLETED	2011-11-01	2006-08-01	NYU Langone Health	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	16	RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	true	The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potential. Growth hormone ...	Hypothyroidism is often associated with growth failure. It takes several years for slow growth to be noticed. This growth retardation is typically severe and progressive. Thyroid hormone is necessary for normal growth. Treatment with thyroxine (thyroid hormone) results in rapid catch-up growth, which mostly happens du...	Hypothyroidism	Hypothyroidism Growth hormone	null	3	arm 1: Group 1 will be treated only with Synthroid. arm 2: Group 2 will be treated with Growth hormone, synthroid, and lupron. arm 3: Group 3 will have acute hypothyroidism and will serve as controls.	[ 4, 0, 4 ]	2	[ 0, 0 ]	intervention 1: Growth hormone + Synthroid + Lupron intervention 2: Lupron once a month and growth hormone daily	intervention 1: Growth hormone intervention 2: Growth hormone treatment and puberty	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	16	0	0	0	NCT00206375	6TERMINATED	2011-11-01	2003-05-01	Baylor College of Medicine	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 0 ]	10	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	true	The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients with cancers or blood diseases, who have poor potential for a cure with standard treatment, will be able to participate in the study. Do...	This study is a single-arm, non-randomized trial. Patients meeting the criteria for this study will be entered sequentially until completion or closure of the study. Early stopping rules will be employed to ascertain whether an unacceptable rate of toxicity (non-engraftment, and/or acute GvHD) occurs. Patients will be...	Hematologic Diseases Hematologic Malignancies	G-CSF Bone Marrow Hematologic malignancies Non-malignancies Matched sibling donor Allogeneic BMT	null	1	arm 1: None	[ 5 ]	1	[ 0 ]	intervention 1: Granulocyte Colony Stimulating Factor	intervention 1: Granulocyte Colony Stimulating Factor	1	Atlanta \| Georgia \| United States \| -84.38798 \| 33.749	10	0	0	0	NCT00231309	1COMPLETED	2011-11-01	2003-07-01	Emory University	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 2 ]	64	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.	This is a Phase Ib open-label, two-arm, dose-finding study of E7389 in combination with carboplatin in patients with solid tumors.	Cancer		null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m\^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion ...	intervention 1: E7389 + carboplatin AUC 5 intervention 2: E7389 + carboplatin AUC 6 intervention 3: E7389+carboplatin AUC 6	11	New Brunswick \| New Jersey \| United States \| -74.45182 \| 40.48622 Lake Success \| New York \| United States \| -73.71763 \| 40.77066 New York \| New York \| United States \| -74.00597 \| 40.71427 The Bronx \| New York \| United States \| -73.86641 \| 40.84985 Graz \| N/A \| Austria \| 15.45 \| 47.06667 Salzburg \| N/A \| Austria \| 13.04...	64	0	0	0	NCT00268905	1COMPLETED	2011-11-01	2006-10-01	Eisai Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	33	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1. To determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variable...	Specific Aims: 1. To examine the effects of sixteen weeks of treatment with the selective serotonin reuptake inhibitor (SSRI) citalopram compared to placebo on executive function in patients with early Huntington's disease (HD). 2. To study the relationship between executive function and functional status in patients ...	Huntington Disease Chorea Executive Dysfunction	Huntington Disease Citalopram Celexa Chorea Focus ADD ADHD HD SSRI	null	2	arm 1: 20mg daily citalopram arm 2: Matching daily placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks intervention 2: a daily matching placebo administered over 16 weeks	intervention 1: 20mg daily citalopram intervention 2: Placebo	3	Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Iowa City \| Iowa \| United States \| -91.53017 \| 41.66113 Rochester \| New York \| United States \| -77.61556 \| 43.15478	33	0	0	0	NCT00271596	1COMPLETED	2011-11-01	2005-11-01	University of Iowa	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	29	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	1FEMALE	false	This study will determine the effectiveness of the antibiotic erythromycin in enhancing gastrointestinal function and decreasing the frequency of binge eating in people with bulimia nervosa.	Bulimia nervosa (BN) is a serious eating disorder that is characterized by frequent uncontrolled eating binges. These binges are often followed by compensatory behavior, including the following: self-induced vomiting; misuse of laxatives, diuretics, enemas, or other medications to induce purging; fasting; or excessive ...	Bulimia Nervosa Eating Disorders	Binge-Eating Disorder	null	2	arm 1: Subjects with Bulimia Nervosa will take erythromycin. arm 2: Participants will take matched placebo.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks intervention 2: Placebo, 250 mg or 500 mg, three times a day for 6 weeks	intervention 1: Erythromycin intervention 2: Placebo	1	New York \| New York \| United States \| -74.00597 \| 40.71427	29	0	0	0	NCT00304187	1COMPLETED	2011-11-01	2004-09-01	New York State Psychiatric Institute	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	3,323	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.	SYR-322 (alogliptin) is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. It is expected tha...	Diabetes Mellitus	Glucose Metabolism Disorder Dysmetabolic Syndrome Type II Diabetes Diabetes Mellitus, Lipoatrophic Dyslipidemia Drug Therapy	null	2	arm 1: Alogliptin 12.5 tablet, orally, once daily for up to 4 years. arm 2: Alogliptin 25 mg tablet, orally, once daily for up to 4 years.	[ 0, 0 ]	1	[ 0 ]	intervention 1: Alogliptin tablets.	intervention 1: Alogliptin	114	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Artesia \| California \| United States \| -118.08312 \| 33.86585 Fresno \| California \| Uni...	3,320	0	0	0	NCT00306384	1COMPLETED	2011-11-01	2006-03-01	Takeda	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	50	NA	SINGLE_GROUP	1PREVENTION	0NONE	false	1FEMALE	true	RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin may keep cancer from coming back in women who are at high risk for a new breast cancer after undergoing surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cance...	OBJECTIVES: Primary * Describe changes from baseline in a panel of biomarkers (high-sensitivity C-reactive protein \[hsCRP\], lipid profile, circulating estrogens, and contralateral breast density) in women at high risk of developing new breast cancer who have undergone surgical resection for history of ductal carcin...	Breast Cancer	breast cancer ductal breast carcinoma in situ breast cancer in situ stage I breast cancer stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer	null	1	arm 1: Simvastatin 40 mg for 24-28 weeks	[ 0 ]	1	[ 0 ]	intervention 1: 24-28 weeks of simvastatin	intervention 1: simvastatin	2	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	50	0	0	0	NCT00334542	1COMPLETED	2011-11-01	2006-03-01	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	329	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	In treatment naïve HIV infected subjects, combination antiretroviral therapy including efavirenz combined with tenofovir and emtricitabine will offer non-inferior antiretroviral efficacy over 48 weeks, compared to either atazanavir boosted with ritonavir combined with tenofovir and emtricitabine or tenofovir and emtric...	The primary objective of this study is to compare the virological efficacy, as measured by the time-weighted mean change from baseline plasma HIV-RNA, and safety, of three strategic regimens of initial antiretroviral therapy (ART) containing a fixed dose formulation of tenofovir and emtricitabine, with either efavirenz...	Human Immunodeficiency Virus (HIV)	Human Immunodeficiency Virus (HIV)	null	3	arm 1: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz) arm 2: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV) arm 3: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)	[ 1, 1, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily intervention 2: Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food) intervention 3: Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd ...	intervention 1: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz) intervention 2: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV) intervention 3: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC...	0	null	323	0	0	0	NCT00335322	1COMPLETED	2011-11-01	2007-02-01	Kirby Institute	2OTHER_GOV	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	25	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed by single agent erlotinib for a total of 12 months.	PATIENT POPULATION Resected pancreatic cancer patients (R0 resection) within 10 weeks of surgery will be eligible, provided that they meet standard eligibility criteria. STUDY DESIGN Phase II, open-label trial of erlotinib and gemcitabine. SAFETY PLAN Safety as assessed by CTCAE 3.0 STUDY TREATMENT Erlotinib 150 mg/da...	Pancreatic Cancer	Pancreas Cancer Pancreatic	null	1	arm 1: Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months	[ 0 ]	2	[ 0, 0 ]	intervention 1: 1500mg/m2 IV over 150 min IV q 2 weeks 4 months intervention 2: 150 mg/d Daily, oral 12 months	intervention 1: Gemcitabine intervention 2: Erlotinib	1	Pittsburgh \| Pennsylvania \| United States \| -79.99589 \| 40.44062	25	0	0	0	NCT00336700	6TERMINATED	2011-11-01	2006-06-01	Herbert J. Zeh, III MD, FACS	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	11	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	false	RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive breast cancer, ductal carcinoma in situ, or a high risk of breast cancer. PURPOSE: This pha...	OBJECTIVES: Primary * Assess the effects of concurrent anastrozole and simvastatin on anastrozole's steady-state concentration in postmenopausal women with history of invasive breast cancer or ductal carcinoma in situ or at high risk for developing breast cancer. Secondary * Study the effect of concurrent simvastat...	Breast Cancer	breast cancer breast cancer in situ ductal breast carcinoma in situ stage I breast cancer stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer	null	1	arm 1: This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.	[ 0 ]	4	[ 0, 0, 10, 3 ]	intervention 1: 1 milligram tablet PO QD for 14 days intervention 2: 40 milligram tablet PO QD for 14 days intervention 3: laboratory analysis intervention 4: laboratory analysis	intervention 1: anastrozole intervention 2: simvastatin intervention 3: pharmacological study intervention 4: adjuvant therapy	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	11	0	0	0	NCT00354640	1COMPLETED	2011-11-01	2006-06-01	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	606	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	2MALE	true	The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis. Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washin...	OBJECTIVES The primary objective of this study is to determine the relative effectiveness of azithromycin and doxycycline in eradicating Mycoplasma genitalium and Ureaplasmas among men with nongonococcal urethritis (NGU). Secondary objectives of this study are to: * determine the sensitivity of persisting organisms ...	Urethritis	NGU, M genitalium, Ureaplasma, azithromycin, doxycycline	null	2	arm 1: Active azithromycin (1g) and placebo doxycycline arm 2: Active doxycycline and placebo azithromycin	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: two 500mg tablets or four 250mg tablets administered as a single dose intervention 2: one 100mg capsule administered twice daily for seven days	intervention 1: Azithromycin intervention 2: Doxycycline	1	Seattle \| Washington \| United States \| -122.33207 \| 47.60621	606	0	0	0	NCT00358462	1COMPLETED	2011-11-01	2007-01-01	University of Washington	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	10	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This phase II trial is studying how well AZD0530 works in treating patients with previously treated metastatic colon cancer or rectal cancer. AZD0530 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.	PRIMARY OBJECTIVES: I. Determine the progression-free survival (PFS) at 4 months in metastatic colorectal carcinoma patients receiving daily doses of AZD0530. SECONDARY OBJECTIVES: I. Evaluate the objective response rate (RR) and overall survival (OS) of patients with metastatic colorectal cancer who are treated wit...	Adenocarcinoma of the Colon Adenocarcinoma of the Rectum Recurrent Colon Cancer Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer		null	1	arm 1: Patients receive oral AZD0530 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	[ 0 ]	2	[ 0, 10 ]	intervention 1: Given orally intervention 2: Correlative studies	intervention 1: saracatinib intervention 2: laboratory biomarker analysis	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	10	0	0	0	NCT00397878	6TERMINATED	2011-11-01	2006-11-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	60	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The goal of this clinical research study is to compare the effectiveness of 2 different doses of the drug clofarabine that can be given on a weekly schedule for the treatment of Myelodysplastic Syndrome (MDS). The safety of these two doses will also be compared. Primary Objective: Compare the response rates of two dos...	Clofarabine is a new chemotherapy drug that is designed to interfere with the growth and development of cancer cells. If you are found to be eligible to take part in this study, you will be randomly assigned (as in the toss of a coin) to one of two treatment groups (Groups A and B). Participants in Group A will receiv...	Myelodysplastic Syndrome Leukemia	Myelodysplastic Syndrome Leukemia Clofarabine MDS	null	2	arm 1: Lower Dose Clofarabine Group A: 15 mg/m\^2 intravenous (IV) over 1 hour daily for 5 days arm 2: Higher Dose Clofarabine Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days	[ 0, 0 ]	1	[ 0 ]	intervention 1: Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days	intervention 1: Clofarabine	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	58	0	0	0	NCT00422032	1COMPLETED	2011-11-01	2006-01-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	30	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving alemtuzumab together with rituximab may kill more canc...	OBJECTIVES: Primary * Determine the rate of complete and overall response to alemtuzumab and rituximab in patients with high-risk, early-stage chronic lymphocytic leukemia. * Determine the toxicity of this regimen in these patients. Secondary * Determine the overall survival and time to progression of patients treate...	Leukemia	stage 0 chronic lymphocytic leukemia stage I chronic lymphocytic leukemia stage II chronic lymphocytic leukemia B-cell chronic lymphocytic leukemia	null	1	arm 1: Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)	[ 0 ]	2	[ 0, 0 ]	intervention 1: 30 mg Monday, Wednesday, and Friday x 5 weeks intervention 2: 375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)	intervention 1: Alemtuzumab intervention 2: Rituximab	1	Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163	30	0	0	0	NCT00436904	1COMPLETED	2011-11-01	2004-12-01	Mayo Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	83	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This 2 arm study will assess the efficacy and safety of two systemic treatments including Avastin in patients with previously-untreated progressive locally advanced/metastatic well-differentiated digestive endocrine tumors. Patients with duodeno-pancreatic tumors (arm 1) will be treated with 5FU/streptozotocin iv (5FU ...	null	Neoplasms		null	2	arm 1: None arm 2: None	[ 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 7.5mg/kg iv on day 1 every 3 weeks intervention 2: 400mg/m2/day iv on days 1-5 every 6 weeks intervention 3: 500mg/m2/day iv on days 1-5 every 6 weeks intervention 4: 1000mg/m2 po bid on days 1-14 every 3 weeks	intervention 1: bevacizumab [Avastin] intervention 2: 5 FU intervention 3: Streptozotocin intervention 4: Xeloda	27	Angers \| N/A \| France \| -0.55202 \| 47.47156 Bordeaux \| N/A \| France \| -0.5805 \| 44.84044 Boulogne-Billancourt \| N/A \| France \| 2.24128 \| 48.83545 Caen \| N/A \| France \| -0.35912 \| 49.18585 Chambray-lès-Tours \| N/A \| France \| 0.70286 \| 47.33537 Clichy \| N/A \| France \| 2.30952 \| 48.90018 Créteil \| N/A \| France \| 2.46569 \|...	83	0	0	0	NCT00448136	1COMPLETED	2011-11-01	2007-07-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	50	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	The purpose of this randomized, Phase 2 open-label study was to assess the response rate of participants with Human Epidermal Growth Factor Receptor 2 (Her2+) locally advanced and/or metastatic breast cancer (not previously treated with chemotherapy or trastuzumab) to treatment with ixabepilone plus trastuzumab and/or ...	null	Metastatic Breast Cancer	Locally advanced and/or metastatic breast cancer	null	2	arm 1: trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m\^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity. arm 2: trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m\^2 IV over 1 hour once ever...	[ 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Ixabepilone 40 mg/m\^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day ...	intervention 1: ixabepilone intervention 2: docetaxel intervention 3: trastuzumab	19	Caen \| N/A \| France \| -0.35912 \| 49.18585 Grenoble \| N/A \| France \| 5.71479 \| 45.17869 Saint-Priest-en-Jarez \| N/A \| France \| 4.37678 \| 45.4739 Toulouse \| N/A \| France \| 1.44367 \| 43.60426 Athens \| N/A \| Greece \| 23.72784 \| 37.98376 Athens \| N/A \| Greece \| 23.72784 \| 37.98376 Pireaus \| N/A \| Greece \| N/A \| N/A Bologna ...	48	0	0	0	NCT00490646	1COMPLETED	2011-11-01	2008-02-01	R-Pharm	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3, 4 ]	80	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).	Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for ATC, and no randomized comparative trials have been known to be conducte...	Anaplastic Thyroid Cancer	thyroid neoplasms thyroid cancer thyroid carcinoma	null	2	arm 1: Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2 arm 2: Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1	[ 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles intervention 2: 200mg/m squared on Day 1 intervention 3: 6 AUC on Day 1 following paclitaxel	intervention 1: CA4P intervention 2: paclitaxel intervention 3: carboplatin	41	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Minneapolis \| Minne...	75	0	0	0	NCT00507429	6TERMINATED	2011-11-01	2007-08-01	Mateon Therapeutics	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	475	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to re-evaluate the therapeutic superiority and safety of acupuncture treatment using high quality and large sampled clinical research. The investigators want to provide a preferred treatment protocol, which is effective, safe, and easy to use in clinical practice. This research also clarifi...	Functional constipation is a high morbidity disease. The life-long treatment of functional constipation can seriously impact a patient's quality of life. At present, one of the most frequently used treatment is catharsis, which deals with the symptom. There are three main problems with catharsis. First, there are no lo...	Constipation	Acupuncture Functional constipation	null	3	arm 1: Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20\~60mm until piercing into the muscle layer...	[ 0, 1, 1 ]	3	[ 10, 0, 10 ]	intervention 1: Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain. Once a day, five times a week, four weeks. intervention 2: 20-30ml, once a day before breakfast, for the wh...	intervention 1: deep needling intervention 2: Lactulose intervention 3: shallow needling	1	Beijing \| Beijing Municipality \| China \| 116.39723 \| 39.9075	455	0	0	0	NCT00508482	1COMPLETED	2011-11-01	2008-04-01	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 2, 3 ]	28	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped. The main purpose of this research study is to find the highest dose of RAD001 that can be given safe...	* Participants will be given a supply of the study drug RAD001 to be taken at home. They will be asked to take the study drug every morning on an empty stomach and will be given a study drug diary to record the time/date each time they take RAD001. Each 6 week period of time is called a cycle of study treatment. * We a...	Hepatocellular Carcinoma	liver cancer RAD001	null	1	arm 1: Patients will receive RAD001 10 mg/day orally (6 weeks/cycle). Patients will be continued on treatment until disease progression, limiting toxicity, patient withdrawal of consent, or death.	[ 0 ]	1	[ 0 ]	intervention 1: Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days	intervention 1: RAD001	3	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	28	0	0	0	NCT00516165	1COMPLETED	2011-11-01	2007-08-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	4,665	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	1FEMALE	true	The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoporosis	null	Osteoporosis	Osteoporosis, oral salmon calcitonin, treatment, efficacy, tolerability	null	2	arm 1: SMC021 - Oral Calcitonin arm 2: SMC021 - placebo	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 0.8mg SMC021 - oral calcitonin, once daily intervention 2: SMC021 - Placebo, once daily	intervention 1: SMC021 Oral calcitonin intervention 2: SMC021 Placebo	16	Gainesville \| Georgia \| United States \| -83.82407 \| 34.29788 Detroit \| Michigan \| United States \| -83.04575 \| 42.33143 Portland \| Oregon \| United States \| -122.67621 \| 45.52345 Rio de Janeiro \| N/A \| Brazil \| -43.18223 \| -22.90642 Beijing \| N/A \| China \| 116.39723 \| 39.9075 Pardubice \| N/A \| Czechia \| 15.77659 \| 50.040...	4,665	0	0	0	NCT00525798	1COMPLETED	2011-11-01	2007-03-01	Nordic Bioscience A/S	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 0 ]	24	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the newer antipsychotics are risk factors for development of diabetes. Subjects with these risk factors plus obesity and/or family history of diabetes who agree to study participation will undergo an oral glucose tolerance test. I...	null	Schizophrenia Schizoaffective Disorder Bipolar Disorder	schizophrenia antipsychotics diabetes bipolar disorder	null	2	arm 1: Subjects stay on same daily oral antipsychotic treatment as at baseline. Dose adjustments allowable as clinically indicated. arm 2: Subjects switch to daily oral ziprasidone from current antipsychotic(s). Dose titrated to clinically effective level.	[ 4, 1 ]	1	[ 0 ]	intervention 1: Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic	intervention 1: ziprasidone	1	San Antonio \| Texas \| United States \| -98.49363 \| 29.42412	24	0	0	0	NCT00538642	1COMPLETED	2011-11-01	2007-08-01	The University of Texas Health Science Center at San Antonio	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3, 4 ]	236	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this project is to compare the efficacy (how successful) 1) standard-dose proton pump inhibitor (PPI) (rabeprazole 20 mg once daily) (a medication that completely blocks the stomach from producing acid) plus low dose tricyclic antidepressant (nortriptyline 50mg) (TCA); 2) double-dose PPI (rabeprazole 20 ...	Failure of standard dose PPI to control GERD symptoms has been increasingly encountered in clinical practice (both primary care and sub-specialties) and has become one of the most challenging therapeutic dilemmas in GERD management. It has been estimated that up to 30% of the patients receiving PPI once daily will cont...	Gastroesophageal Reflux Disease	acid reflux acid regurgitation esophagitis GERD heartburn pain peptic	null	3	arm 1: AciPhex 20 mg BID and once daily placebo arm 2: AcipHex 20 mg once daily and BID placebo arm 3: AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily	[ 2, 2, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime intervention 2: Breakfast \& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime intervention 3: Rabeprazole (Breakfast) study medication, dinner...	intervention 1: Rabeprazole 20mg, placebo dinner and bedtime intervention 2: Rabeprazole 20 mg two times, Placebo at bedtime intervention 3: Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant	1	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174	168	0	0	0	NCT00539240	1COMPLETED	2011-11-01	2006-04-01	US Department of Veterans Affairs	1FED	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	7	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. Giv...	OBJECTIVES: * To evaluate the effectiveness of neoadjuvant dose-dense chemotherapy comprising doxorubicin hydrochloride, ifosfamide, and irinotecan hydrochloride in combination with dexrazoxane hydrochloride followed by surgery and radiotherapy in patients with advanced soft tissue sarcoma or recurrent bone sarcoma. *...	Sarcoma	recurrent adult soft tissue sarcoma stage III adult soft tissue sarcoma stage IV adult soft tissue sarcoma metastatic osteosarcoma recurrent osteosarcoma metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor Ewing sarcoma of bone	null	1	arm 1: High-dose chemotherapy with doxorubicin at 120 mg/m2 and ifosfamide at 2 g/m2 followed by a prolonged schedule of CPT-11 at 20 mg/m2.	[ 0 ]	11	[ 2, 0, 0, 0, 0, 6, 10, 3, 3, 3, 4 ]	intervention 1: None intervention 2: None intervention 3: None intervention 4: None intervention 5: None intervention 6: None intervention 7: None intervention 8: None intervention 9: None intervention 10: None intervention 11: None	intervention 1: filgrastim intervention 2: dexrazoxane hydrochloride intervention 3: doxorubicin hydrochloride intervention 4: ifosfamide intervention 5: irinotecan hydrochloride intervention 6: protein expression analysis intervention 7: immunoenzyme technique intervention 8: adjuvant therapy intervention 9: conventio...	0	null	7	0	0	0	NCT00544778	6TERMINATED	2011-11-01	2001-08-01	City of Hope Medical Center	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	11	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	true	0ALL	false	This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal c...	Psychopharmacological modulation of the catecholaminergic system can enhance some aspects of cognitive function. For example, catechol-O-methyltransferase (COMT) inhibitors such as tolcapone can improve working memory/executive function. Similarly, modafinil, a catecholaminergic agonist with norepinephrine (NA) reuptak...	Schizophrenia Memory Disorders Cognition Disorders	Genes Dorsolateral Prefrontal Cortex Dopamine Functional Magnetic Resonance Imaging Neuropsychological Testing Schizophrenia Atomoxetine Cognitive Study Pharmacogenetics Normal Volunteers Catechol-O-Methyltransferase Healthy Volunteer	null	2	arm 1: Atomoxetine 80 mg final dose. Arm lasts 14 days. Schedule 25 mg Day 1 (or Day 22), 40 mg Day 2-3 (or Days 23-24), 60 mg Days 4-5 (or Days 25-26), 80 mg Days 6-14 (or Days 27-35). After 14 days, subjects undergo functional magnetic resonance imaging (MRI) and neuropsychological testing in addition to psychopath...	[ 1, 2 ]	4	[ 0, 3, 3, 0 ]	intervention 1: Comparison between Atomoxetine and Placebo intervention 2: Comparison between Atomoxetine and Placebo arms intervention 3: Comparison between Atomoxetine and Placebo arms intervention 4: 25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo	intervention 1: Atomoxetine intervention 2: Functional magnetic resonance imaging intervention 3: Neuropsychological Testing intervention 4: Placebo	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	22	0	0	0	NCT00548327	6TERMINATED	2011-11-01	2007-10-01	National Institute of Mental Health (NIMH)	0NIH	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	1,457	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. The efficacy of SD-6010 will be evaluated by radiography using joint space narrowing in...	null	Osteoarthritis	knee Osteoarthritis Disease Modifying Osteoarthritis Drug	null	3	arm 1: High dose active comparator arm 2: Low dose active comparator arm 3: Placebo comparator to be used for control purposes	[ 1, 1, 2 ]	3	[ 0, 0, 0 ]	intervention 1: 200 mg tablets once a day for 2 years intervention 2: 50 mg tablets once a day for 2 years intervention 3: Placebo tablets once a day for 2 years	intervention 1: SD-6010 intervention 2: SD-6010 intervention 3: Placebo	183	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Tucson \| Arizona \| United St...	1,452	0	0	0	NCT00565812	1COMPLETED	2011-11-01	2007-11-01	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	127	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	Depression is commonly seen in patients with cardiovascular disorders. In recent studies it has been shown that mild to moderate depression symptoms were associated with increased likelihood of mental stress-induced myocardial ischemia (MSIMI), which is a risk factor of poor cardiac outcome. In this project, the invest...	The goals of this project are to investigate the response of mental stress-induced myocardial ischemia (MSIMI) to escitalopram, a selective serotonin reuptake inhibitor (SSRI); to determine whether MSIMI will be reduced by the treatment, and whether the modification of MSIMI is related to improvement of depression symp...	Myocardial Ischemia	ischemic heart disease mental stress-induced myocardial ischemia escitalopram	null	2	arm 1: Escitalopram treatment arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed. intervention 2: Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in...	intervention 1: Escitalopram intervention 2: Placebo	1	Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	127	0	0	0	NCT00574847	1COMPLETED	2011-11-01	2006-09-01	Duke University	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	5	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving irinotecan together with cediran...	OBJECTIVES: Primary * To determine the proportion of patients who are free from progression at 12 weeks from the start of second-line therapy. Secondary * To determine objective response rate. * To determine overall survival. * To further define the dosing and safety profile of irinotecan hydrochloride and cedirani...	Colorectal Cancer	stage IV colon cancer stage IV rectal cancer recurrent colon cancer recurrent rectal cancer	null	1	arm 1: Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up every 3 mont...	[ 0 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: cediranib maleate intervention 2: irinotecan hydrochloride	31	Evanston \| Illinois \| United States \| -87.69006 \| 42.04114 Elkhart \| Indiana \| United States \| -85.97667 \| 41.68199 Elkhart \| Indiana \| United States \| -85.97667 \| 41.68199 Fort Wayne \| Indiana \| United States \| -85.12886 \| 41.1306 Kokomo \| Indiana \| United States \| -86.1336 \| 40.48643 La Porte \| Indiana \| United State...	4	0	0	0	NCT00588900	6TERMINATED	2011-11-01	2008-03-01	Alliance for Clinical Trials in Oncology	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	40	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The primary objective of this study is to gather preliminary data regarding the angiographic efficacy of the administration of low-dose adjunctive intracoronary (IC) tenecteplase during balloon angioplasty for heart attacks. We hypothesize that low-dose IC tenecteplase will enhance the breakdown of blood clots at the ...	The primary objective of this study is to gather preliminary data regarding the angiographic efficacy of the administration of low-dose adjunctive intracoronary (IC) tenecteplase during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Efficacy will be assessed by ...	Acute Myocardial Infarction	ST-Elevation Myocardial Infarction Acute Myocardial Infarction No Reflow	null	2	arm 1: Two (4mg) doses of tenecteplase arm 2: Two (4mL) doses of sterile saline	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Intracoronary injection of IV tenecteplase. intervention 2: Intracoronary injection of IV sterile saline	intervention 1: Tenecteplase intervention 2: Sterile Saline	8	Gainesville \| Florida \| United States \| -82.32483 \| 29.65163 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Decatur \| Georgia \| United States \| -84.29631 \| 33.77483 Decatur \| Georgia \| United States \| -84.29631 \| 33.77483 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Rochester \| Michigan \| Unite...	36	0	0	0	NCT00604695	1COMPLETED	2011-11-01	2008-07-01	C. Michael Gibson, MS, MD	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	6	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	true	Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be required to maintain this effect. It is hypothesized that sustained release fluocinolone acet...	Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be required to maintain this effect. The use of the glucocorticoids such as triamcinolone aceton...	Age Related Macular Degeneration	AMD Almera Steroid Macular ARMD	null	2	arm 1: Dose 0.2 ug/day Medidur implant arm 2: Dose 0.5 ug/day Medidur implant	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: 0.2 ug/day implant intervention 2: 0.5 ug/day implant	intervention 1: Fluocinolone Acetonide/Medidur intervention 2: Fluocinolone Acetonide/Medidur	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	6	0	0	0	NCT00605423	1COMPLETED	2011-11-01	2008-01-01	Johns Hopkins University	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	117	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin (FOLFOX) or 5-FU/LV + irinotecan (FOLFIRI), plus bevacizumab in patients with Metastatic Col...	null	Colorectal Cancer		null	2	arm 1: 5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with enzastaurin arm 2: 5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with placebo	[ 0, 2 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: 1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease intervention 2: oral, daily (up to 1 yr or until progressive disease) intervention 3: 400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until pr...	intervention 1: Enzastaurin intervention 2: Placebo intervention 3: Leucovorin (LV) intervention 4: 5-fluorouracil (5-FU) intervention 5: Bevacizumab (Bev)	26	Memphis \| Tennessee \| United States \| -90.04898 \| 35.14953 Houston \| Texas \| United States \| -95.36327 \| 29.76328 Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078 Innsbruck \| N/A \| Austria \| 11.39454 \| 47.26266 Krems \| N/A \| Austria \| 15.61415 \| 48.40921 Salzburg \| N/A \| Austria \| 13.04399 \| 47.79941 Vienn...	115	0	0	0	NCT00612586	1COMPLETED	2011-11-01	2008-02-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	140	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	To determine whether simvastatin at a dose of 80mg can reduce the rate of whole brain atrophy, as measured by MRI, over a 2-year time-period when compared to placebo.	The study has now completed see Primary publication: Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CR, Clegg ...	Secondary Progressive Multiple Sclerosis	Secondary progressive Multiple Sclerosis Simvastatin MRI	null	2	arm 1: Simvastatin 80mg OD arm 2: Placebo	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 80mg simvastatin oral once daily for 24 months intervention 2: Oral placebo tablet once daily for 24 months	intervention 1: Simvastatin intervention 2: Placebo	3	Chalfont Saint Peter \| Buckinghamshire \| United Kingdom \| -0.55618 \| 51.60885 Hammersmith \| London \| United Kingdom \| -0.22882 \| 51.49384 Brighton \| N/A \| United Kingdom \| -0.13947 \| 50.82838	140	0	0	0	NCT00647348	1COMPLETED	2011-11-01	2008-01-01	Imperial College London	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 5 ]	36	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	null	This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics with persistent symptoms and evidence of airway inflammation despite treatment with inhaled...	null	Allergic Asthma	Asthma, adults, anti-immunoglobulin E ( IgE), omalizumab, airway inflammation, airway remodeling, allergy	null	2	arm 1: Omalizumab was supplied as lyophilized, sterile powder in a single use, 5 ml vial that was designed to deliver 150 mg of omalizumab for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The dose administered was individualized for each patient based on the patient's bo...	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: omalizumab at a dose of 0.016mg/kg/IU/mL intervention 2: Placebo	16	Denver \| Colorado \| United States \| -104.9847 \| 39.73915 St Louis \| Missouri \| United States \| -90.19789 \| 38.62727 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Galvest...	36	0	0	0	NCT00670930	1COMPLETED	2011-11-01	2008-04-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	23	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid Metabolic Syndrome (METSYN).	null	Depressive Disorder, Major Metabolic Syndrome X	Depressive Disorder, Major Metabolic Syndrome X pioglitazone	null	1	arm 1: An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.	[ 0 ]	1	[ 0 ]	intervention 1: An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.	intervention 1: Pioglitazone	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	23	0	0	0	NCT00671515	1COMPLETED	2011-11-01	2008-04-01	Joseph Calabrese, MD	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 4 ]	130	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.	Subjects are randomized to a control group or a treatment group, with the control group crossed over to the treatment group at the 3 month visit. Corneal collagen cross-linking is performed as a single treatment. Subjects are followed for 12 months after the procedure to evaluate the long term effects of corneal collag...	Ectasia	ectasia cross-linking crosslinking cornea riboflavin UVA	null	2	arm 1: riboflavin ophthalmic solution and UVA irradiation arm 2: riboflavin opthalmic solution without UVA irradiation	[ 1, 3 ]	2	[ 0, 1 ]	intervention 1: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL) intervention 2: UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes	intervention 1: riboflavin ophthalmic solution intervention 2: UVA Irradiation	10	La Jolla \| California \| United States \| -117.2742 \| 32.84727 San Diego \| California \| United States \| -117.16472 \| 32.71571 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Kansas City \| Kansas \| United States \| -94.62746 \| 39.11417 Baltimore \| Marylan...	130	0	0	0	NCT00674661	1COMPLETED	2011-11-01	2007-12-01	Glaukos Corporation	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 2 ]	13	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells...	OBJECTIVES: Primary * To determine the maximum tolerated dose of sorafenib tosylate and lenalidomide in combination with dexamethasone in patients with relapsed or refractory multiple myeloma. (phase I) * To describe the toxicity of this regimen in these patients. (phase I) * To evaluate the confirmed response in pat...	Multiple Myeloma and Plasma Cell Neoplasm	refractory multiple myeloma	null	1	arm 1: None	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: 20 mg orally Days 1, 8, 15, 22 of 28 day cycle intervention 2: Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice d...	intervention 1: dexamethasone intervention 2: sorafenib tosylate intervention 3: Lenalidomide	1	Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163	13	0	0	0	NCT00687674	6TERMINATED	2011-11-01	2008-08-01	Mayo Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	45	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with metastatic colorectal cancer with unresectable liver metastasis. Patients will receive Avastin...	null	Colorectal Cancer		null	1	arm 1: None	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: 5mg/kg iv on day 1 of each 2 week cycle. intervention 2: 1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle intervention 3: 85mg/m2 iv on day 1 of each 2 week cycle	intervention 1: bevacizumab [Avastin] intervention 2: capecitabine [Xeloda] intervention 3: oxaliplatin	6	Kaohsiung City \| N/A \| Taiwan \| 120.31333 \| 22.61626 Kaohsiung City \| N/A \| Taiwan \| 120.31333 \| 22.61626 Taichung \| N/A \| Taiwan \| 120.6839 \| 24.1469 Taipei \| N/A \| Taiwan \| 121.52639 \| 25.05306 Taipei \| N/A \| Taiwan \| 121.52639 \| 25.05306 Taoyuan \| N/A \| Taiwan \| 121.29696 \| 24.99368	45	0	0	0	NCT00700570	1COMPLETED	2011-11-01	2008-08-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	2	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	Standard chemotherapy drugs generally work by killing rapidly dividing cells in your body. Cancers cells are some of the most rapidly dividing cells and that is why chemotherapy can be effective in some patients. Gemcitabine and Cisplatin are an effective and standard drug combination used to treat locally advanced and...	null	Bladder Cancer URINARY BLADDER	Bladder Urinary SORAFENIB CISPLATIN GEMCITABINE	null	1	arm 1: This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.	[ 0 ]	1	[ 0 ]	intervention 1: Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until th...	intervention 1: gemcitabine and cisplatin plus sorafenib	1	New York \| New York \| United States \| -74.00597 \| 40.71427	2	0	0	0	NCT00714948	6TERMINATED	2011-11-01	2008-07-01	Memorial Sloan Kettering Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0	0	0	0
[ 3 ]	24	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	Each year 730,000 Americans experience a stroke. Forty percent are left with significant paralysis of one arm. Certain types of physical therapy, for example constraint induced movement therapy (CIMT), have been shown to be effective in improving arm function. However, for most subjects, improvement is modest. In this ...	Each year, 730,000 Americans experience a stroke. Forty percent are left with persistent impairment of upper extremity function. Although scientifically vetted rehabilitation therapies for this impairment are starting to emerge, current treatment is generally unsatisfactory. Therapies that seek to engage neuroplastic m...	Stroke	stroke hemiparesis randomized controlled trial d-cycloserine distributed practice constraint induced movement therapy	null	4	arm 1: D-cycloserine + distributed treatment arm 2: D-cycloserine + condensed treatment arm 3: Placebo + distributed treatment arm 4: Placebo + condensed treatment	[ 0, 3, 2, 2 ]	4	[ 0, 5, 0, 5 ]	intervention 1: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session intervention 2: Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before ea...	intervention 1: D-cycloserine + distributed treatment intervention 2: D-cycloserine + condensed treatment intervention 3: Placebo + distributed treatment intervention 4: Placebo + condensed treatment	1	Gainesville \| Florida \| United States \| -82.32483 \| 29.65163	24	0	0	0	NCT00720759	1COMPLETED	2011-11-01	2009-07-01	US Department of Veterans Affairs	1FED	false	false	false	null	0	0	0	0	0	0	0	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.